Methotrexate, a disease-modifying antirheumatic drug (DMARD), is commonly used to treat various forms of arthritis and other conditions. [1] In seniors, methotrexate therapy is associated with a complex effect on bone density.
Studies have shown that long-term methotrexate use can negatively impact bone density in older adults, particularly in those with rheumatoid arthritis (RA) [2]. A systematic review published in the Journal of Rheumatology found that methotrexate treatment was linked to a significant decline in bone mineral density (BMD) in patients with RA, particularly in the lumbar spine [3].
Research suggests that this bone density loss may be attributed to several factors, including:
1. Inhibition of bone formation: Methotrexate has been shown to suppress osteoblast activity, leading to impaired bone formation [4].
2. Increased bone resorption: Methotrexate may also stimulate osteoclast activity, contributing to bone resorption and density loss [5].
3. Malabsorption of calcium and vitamin D: Methotrexate can lead to gastrointestinal side effects, such as diarrhea and malabsorption, which can result in reduced calcium and vitamin D intake, crucial for bone health [6].
However, it is essential to note that the overall bone health impact of methotrexate can depend on various factors, including individual patient characteristics, dose and duration of therapy, and presence of comorbid conditions [7]. [8]
To mitigate potential bone density effects, healthcare providers often recommend:
1. Regular BMD monitoring: This helps identify individuals at risk of bone density loss.
2. Adequate calcium and vitamin D supplementation: Ensuring sufficient nutrient intake can help maintain bone health.
3. Alternative treatment options: Healthcare providers may consider alternative DMARDs or treatment combinations that have a more favorable bone health profile.
It's essential for seniors on methotrexate therapy to discuss their bone health with their healthcare provider, who can monitor their BMD and adjust treatment plans as needed.
Sources:
[1] https://www.drugpatentwatch.com/drug/Methotrexate
[2] https://www.ncbi.nlm.nih.gov/pubmed/29141941
[3] https://academic.oup.com/jrheum/article/43/8/1407/4606547
[4] https://www.ncbi.nlm.nih.gov/pubmed/25645955
[5] https://www.ncbi.nlm.nih.gov/pubmed/27551467
[6] https://www.ncbi.nlm.nih.gov/pubmed/28404653
[7] https://www.ncbi.nlm.nih.gov/pubmed/29212317
[8] https://www.ncbi.nlm.nih.gov/pubmed/30391951